Nautilus Biotechnology (NAUT) Cash from Operations Growth (5y) (2025 - 2026)

Nautilus Biotechnology (NAUT) Cash from Operations Growth (5y) (2025 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,440.76 Bn	66,440.47 Bn	-
2	Nanobiotix	1,909.20 Bn	1,909.14 Bn	-
3	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-
4	BeOne Medicines	468.28 Bn	463.49 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.49 Bn	115.24 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.26 Bn	61.51 Bn	3.31 Bn
7	Belite Bio	62.88 Bn	62.88 Bn	-
8	Argenx Se	55.67 Bn	50.48 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.37 Bn	34.36 Bn	959.66 Mn
10	Nautilus Biotechnology	209.58 Mn	113.71 Mn	-

Download Data